title: Why Ca2+ antagonists will be most useful before or during early myocardial ischaemia and not after infarction has been established.
authors.forename: P G
authors.initials: PG
authors.lastname: Hugenholtz
authors.forename: P W
authors.initials: PW
authors.lastname: Serruys
authors.forename: A
authors.initials: A
authors.lastname: Fleckenstein
authors.forename: W
authors.initials: W
authors.lastname: Nayler
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000789:Angina, Unstable / Q000188:drug therapy; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003331:Coronary Vessels / Q000187:drug effects; D004359:Drug Therapy, Combination; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D009206:Myocardium / Q000378:metabolism / Q000648:ultrastructure; D009543:Nifedipine / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D009543:Nifedipine